Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aurora Cannabis Inc T.ACB

Alternate Symbol(s):  T.ACB.WS.U | ACB

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company’s principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally, and the propagation of vegetables and ornamental plants in North America. Its segments include Canadian Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. It also has a controlling interest in Bevo Farms Ltd., North America's supplier of propagated vegetables and ornamental plants in North America. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, TerraFarma Inc., Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., among others.


TSX:ACB - Post by User

Bullboard Posts
Comment by rbm0524on Nov 01, 2016 11:03am
121 Views
Post# 25410078

RE:RE:RE:Financials update

RE:RE:RE:Financials updateAurora also provided a $50 credit to each new customer at the time of their first order. This will have impacted average sale price per gram. Average price will increase as revenues now coming from repeat customers.
rokkitt wrote: 2nd follow up:

Aurora can afford to have a lower selling price because their cost to produce is lower.  Similar to many start-ups in rapidly growing industries, the first aim is to acquire market share.  Once a dominant position is established, economies of scale come into play due to sheer size, lowering costs and allowing the behemoths of the industry to turn their gaze toward profitability while slowly increasing prices.

Last point: I doubt very much that the market is saturated.  The industry's patient base is rapidly growing and LPs seem to be struggling to keep pace with demand.  The bottle neck is supply, not demend.


Bullboard Posts